All News

meeting.audience.3.jpg

EULAR 2021 – Day 4 Report

Jack Cush, MD

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
audience learn

EULAR 2021 - Day 3 Report

Jack Cush, MD

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read Article
COVID vaccine vials

Israel provides COVID vaccine answers for rheumatic disease patients

David Liew, FRACP

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Read Article
The FDA has informed Abbvie that their supplemental application for new indications (PsA and AS) for upadacitinib (Rinvoq) has been delayed; the FDA citing its ongoing review of tofacitinibs safety concerns stemming from the ORAL Surveillance RA study https://t.co/sSJyVtQNYu

Links:

Dr. John Cush RheumNow ( View Tweet)

Ten Things to Tell Patients About Diet and Rheumatic Disease: Dr. Eric Dein ( @ejdein1 ) https://t.co/q2Mc1gLZig https://t.co/iV5JO8m5Sv

Links:

Dr. John Cush RheumNow ( View Tweet)
Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi ( @MeralElRamahiMD ) reviews the panel from #EULAR2021. https://t.co/pfYvfsCbiA

Links:

Dr. John Cush RheumNow ( View Tweet)

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. We've compiled some of the highlights. https://t.co/NbBqPbbiUy https://t.co/FvsOhKtrHi

Links:

Dr. John Cush RheumNow ( View Tweet)
Why do female counterparts axSpA patients report worsening outcomes and worsening scores compared to their male counterparts? https://t.co/6hXp4Lemyk https://t.co/RTuhATrtG9

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021 https://t.co/ocyR4ka8zO https://t.co/DxHjM0stKo

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 - Day 3 Report https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo

Links:

Dr. John Cush RheumNow ( View Tweet)
Find all your AS/Spondyloarthritis coverage from #EULAR2021 in one spot. https://t.co/owm8LQzHXr https://t.co/5YmDFOvolF

Links:

Dr. John Cush RheumNow ( View Tweet)
OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#EULAR2021 POS0236 Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort ⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA Can use to counsel AxSpA patients that we have effective Rx for return to work @RheumNow

Eric Dein ejdein1 ( View Tweet)

#EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA. ⭐️Dysbiosis in 33% of AxSpA vs 17% of controls wo rheumatic disease ⭐️Gut dysbiosis associated with worsening disease activity @RheumNow https://t.co/rRl4Zbs7xc
Eric Dein ejdein1 ( View Tweet)
6. Rheum disease activity was stable with COVID vaccination. (RA, PsA, axSpA, SLE - total n = 597) 7/ LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew drdavidliew ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×